Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 1;33(8):542-550.
doi: 10.1097/FBP.0000000000000701. Epub 2022 Oct 18.

Long-term follow-up of intracerebroventricular injection of streptozotocin-inducing pain sensitization

Farzaneh Rostami  1 , Zohreh Abbasi, Masoud Fereidoni
Affiliations

Long-term follow-up of intracerebroventricular injection of streptozotocin-inducing pain sensitization

Farzaneh Rostami et al. Behav Pharmacol. .

Abstract

Age is known to be the major risk factor for both pain sensation and sporadic Alzheimer's disease (sAD). Pain management in AD is a critical health condition. However, assessing pain in sAD patients is challenging. The intracerebroventricularly injected streptozotocin (icv-STZ) rat model of sAD has been brought to the fore as a hopefully suitable model that could mimic some features of sAD. However, the exact mechanism by which this agent may induce AD-like pathology is largely unknown. In some studies, analgesic drugs have been suggested as possible prevention of AD and icv-STZ-induced AD-like pathology. Therefore, this study used formalin and tail-flick tests to investigate whether different doses of icv-STZ injections could affect acute and inflammatory pain sensation and edema volume over time. Behavioral responses were observed at four testing time points (1, 2.5, 3.5, and 6 months postinjection). The results indicate that icv-STZ was able to significantly decrease the animals' formalin pain threshold in both a time- and dose-dependent manner. Formalin-induced acute and chronic pain scores of animals treated with streptozotocin 3 mg/kg (STZ3) increased dramatically 2.5 months after injection and persisted thereafter. The augmentation in pain score induced by streptozotocin 1 mg/kg (STZ1) was observed from 3.5 months after STZ injection. However, the effect of streptozotocin 0.5 mg/kg (STZ0.5) was NS until 6 months after injection. However, formalin-induced paw edema occurred with a longer delay and was not detectable in STZ0.5-treated animals. In addition, only STZ3-treated animals significantly reduced the thermal pain threshold of animals 6 months after injection. These observations indicate that icv-STZ can sensitize central and/or peripheral receptors to pain. The effect of STZ is dose- and time-dependent. AD-like pathology induced by icv-STZ could be partially activated via pain processing pathways. Therefore, anti-inflammatory agents could alleviate AD-like symptoms via pain treatments.

PubMed Disclaimer

References

    1. Aman Y, Pitcher T, Ballard C, Malcangio M (2019). Impaired chronic pain-like behaviour and altered opioidergic system in the TASTPM mouse model of Alzheimer’s disease. Eur J Pain 23:91–106.
    1. Apkarian A.V, Scholz J (2006). Shared mechanisms between chronic pain and neurodegenerative disease. Drug Discov Today Dis Mech 3:319–326.
    1. Bannon AW, Malmberg AB (2007). Models of nociception: hot-plate, tail-flick, and formalin tests in rodents. 41, 8.9. 1–8.9. 16.
    1. Beach PA, Humbel A, Dietrich MS, Bruehl S, Cowan RL, Moss KO, Monroe TB (2022). A cross-sectional study of pain sensitivity and unpleasantness in people with vascular dementia. Pain Med 23:1231–1238.
    1. Benedetti F, Vighetti S, Ricco C, Lagna E, Bergamasco B, Pinessi L, Rainero I (1999). Pain threshold and tolerance in Alzheimer’s disease. Pain 80:377–382.

Publication types